Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of 'post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes...

Bibliografske podrobnosti
Main Authors:	Hurst, J, Hoffmann, M, Pace, M, Williams, J, Thornhill, J, Hamlyn, E, Meyerowitz, J, Willberg, C, Koelsch, K, Robinson, N, Brown, H, Fisher, M, Kinloch, S, Cooper, D, Schechter, M, Tambussi, G, Fidler, S, Babiker, A, Weber, J, Kelleher, A, Phillips, R, Frater, A
Format:	Journal article
Jezik:	English
Izdano:	Nature Publishing Group 2015

Podobne knjige/članki

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection
od: Hamlyn, E, et al.
Izdano: (2012)

HIV-1 DNA predicts disease progression and post-treatment virological control.
od: Williams, J, et al.
Izdano: (2014)

Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection
od: Hoffmann, M, et al.
Izdano: (2016)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
od: Gossez, M, et al.
Izdano: (2018)

Enrichment of the HIV reservoir in CD32+CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression
od: Martin, GE, et al.
Izdano: (2017)

Treatment interruption in chronic HIV-1 infection: does it deliver?
od: Willberg, C, et al.
Izdano: (2007)

Levels of human immunodeficiency virus DNA are determined before art initiation and linked to CD8 T-cell activation and memory expansion
od: Martin, GE, et al.
Izdano: (2019)

Beating atomic swords into immunological ploughshares.
od: Frater, J, et al.
Izdano: (2011)

Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection
od: Hamlyn, E, et al.
Izdano: (2010)

Short-course antiretroviral therapy in primary HIV infection.
od: Fidler, S, et al.
Izdano: (2013)

HCV immunology--death and the maiden T cell.
od: Willberg, C, et al.
Izdano: (2003)

Advancing the HIV cure agenda: the next 5 years.
od: Thornhill, J, et al.
Izdano: (2015)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
od: Stöhr, W, et al.
Izdano: (2013)

CD32-expressing CD4 T cells are phenotypically diverse and can contain proviral HIV DNA
od: Martin, G, et al.
Izdano: (2018)

The immunological and virological consequences of planned treatment interruptions in children with HIV infection
od: Klein, N, et al.
Izdano: (2013)

CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype
od: Thornhill, J, et al.
Izdano: (2019)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
od: Fidler, S, et al.
Izdano: (2002)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
od: Fidler, S, et al.
Izdano: (2002)

HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
od: Scriba, T, et al.
Izdano: (2005)

HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
od: Scriba, T, et al.
Izdano: (2005)

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
od: Gunst, JD, et al.
Izdano: (2025)

A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study
od: Fidler, S, et al.
Izdano: (2017)

Liver cell lines for the study of hepatocyte functions and immunological response.
od: Clayton, R, et al.
Izdano: (2005)

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
od: Touloumi, G, et al.
Izdano: (2006)

Human immunodeficiency virus infection impairs Th1 and Th17 Mycobacterium tuberculosis–specific T-cell responses
od: Murray, L, et al.
Izdano: (2018)

Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection
od: Muenchhoff, M, et al.
Izdano: (2016)

Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection
od: Frater, J, et al.
Izdano: (2019)

HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression in the SPARTAC Trial
od: Frater, A, et al.
Izdano: (2013)

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
od: Angus, B, et al.
Izdano: (2008)

Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.
od: Holodniy, M, et al.
Izdano: (2011)

The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery.
od: Thornhill, J, et al.
Izdano: (2017)

Identifying the limits of the rebound effect
od: Fawcett, T
Izdano: (2020)

Physical chemistry: When molecules don't rebound.
od: Brouard, M
Izdano: (2008)

The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS)
od: Fox, J, et al.
Izdano: (2009)

HIV-1 drug resistance in primary infections in the UK.
od: Fidler, S, et al.
Izdano: (2001)

Structured observations reveal slow HIV-1 CTL escape
od: Roberts, H, et al.
Izdano: (2015)

The rebound of non-spherical particles in gas turbine components
od: Gaskell, JG, et al.
Izdano: (2021)

Operational complexity and supplier-customer integration: case study insights and complexity rebound.
od: Sivadasan, S, et al.
Izdano: (2010)

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
od: Touloumi, G, et al.
Izdano: (2008)

Curing HIV by 'kick and kill': from theory to practice?
od: Pace, M, et al.
Izdano: (2019)